These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 9523734

  • 21. Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study.
    Nicoletto MO, Padrini R, Palumbo M, Ziade A, Ragazzi RS, Pratesi G, Artioli G, De Cesare M, Zunino F.
    Oncol Rep; 2002; 9(6):1351-4. PubMed ID: 12375047
    [Abstract] [Full Text] [Related]

  • 22. p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma.
    Oggionni M, Pilotti S, Suardi S, Ditto A, Luoni C, Mariani L, Scambia G, Fanfani F, Zunino F.
    Oncology; 2005; 69(2):154-8. PubMed ID: 16127286
    [Abstract] [Full Text] [Related]

  • 23. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
    Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M.
    Cancer Biol Ther; 2010 Dec 01; 10(11):1137-46. PubMed ID: 20935474
    [Abstract] [Full Text] [Related]

  • 24. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
    Jonsson E, Fridborg H, Nygren P, Larsson R.
    Eur J Clin Pharmacol; 1998 Sep 01; 54(7):509-14. PubMed ID: 9832291
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 01; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 27. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC, Motzer RJ, Tong Y, Bosl GJ.
    J Natl Cancer Inst; 1994 Oct 19; 86(20):1517-24. PubMed ID: 7932806
    [Abstract] [Full Text] [Related]

  • 28. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents.
    Tong X, Shine DH, Agoulnik I, Freund CT, Hasenburg A, Aguilar-Cordova E, Woo SL, Kieback DG.
    Anticancer Res; 1998 Oct 19; 18(5A):3421-6. PubMed ID: 9858918
    [Abstract] [Full Text] [Related]

  • 29. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ, Moyer JD, Suffness M, Harrison SD, Cysyk R, Hamilton TC, Plowman J.
    Cancer Res; 1994 Feb 01; 54(3):724-9. PubMed ID: 8306334
    [Abstract] [Full Text] [Related]

  • 30. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, Poupon MF.
    Clin Cancer Res; 2000 May 01; 6(5):2075-86. PubMed ID: 10815935
    [Abstract] [Full Text] [Related]

  • 31. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA, Dorton R, Bloomfield A, Nelson M, Vetzel M, Guan J, Leamon CP.
    Clin Cancer Res; 2014 Apr 15; 20(8):2104-14. PubMed ID: 24429878
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
    Emerson DL, Besterman JM, Brown HR, Evans MG, Leitner PP, Luzzio MJ, Shaffer JE, Sternbach DD, Uehling D, Vuong A.
    Cancer Res; 1995 Feb 01; 55(3):603-9. PubMed ID: 7834631
    [Abstract] [Full Text] [Related]

  • 35. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 36. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
    van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH.
    J Biol Chem; 2004 Dec 24; 279(52):54502-9. PubMed ID: 15471886
    [Abstract] [Full Text] [Related]

  • 37. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ.
    Gynecol Oncol; 2006 Apr 24; 101(1):46-54. PubMed ID: 16271751
    [Abstract] [Full Text] [Related]

  • 38. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G.
    Clin Cancer Res; 1998 Apr 24; 4(4):985-92. PubMed ID: 9563894
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.